Tissue engineering and cell therapy hold great promise clinically. In this regard, multipotent cells, such as mesenchymal stem cells (MSCs), may be used therapeutically, in the near future, to restore function to damaged organs. Nevertheless, several technical issues, including the highly invasive procedure of isolating MSCs and the inefficiency surrounding their amplification, currently hamper the potential clinical use of these therapeutic modalities. Moreover, as in the generation of iPS cells, all tissue engineering therapies must also produce cells free of external gene transductions in order to maintain patient safety. On the other hand, MSCs, adipocyte-derived stem cells (ASCs) can be isolated from fat with very easy technique and will be amplified under many cell culture conditions. As such, it is considered a highly useful experimental and medical tools in the field of regenerative medicine. In fact, from animal model to clinical studies, use of ASCs in the treatment of several diseases, including graft-versus-host disease and peripheral artery disease, has shown promise. Therefore, our research focus is to establish ASCs-based stem cell therapy as a regenerative medicine. We are especially interested in the role of noncoding RNAs, transcriptional factors, and epigenetic regulators in controlling the capacity of differentiation of ASCs  to multiple cell types as well as the beneficial use of ASCs in reproduction field. We are interested in studying epigenetic control and the action of non coding RNAs in the mesenchymal stem cell differentiation.